TY - JOUR
T1 - Prostate-specific membrane antigen-targeted radiohalogenated PET and therapeutic agents for prostate cancer
AU - Rowe, Steven P.
AU - Drzezga, Alexander
AU - Neumaier, Bernd
AU - Dietlein, Markus
AU - Gorin, Michael A.
AU - Zalutsky, Michael R.
AU - Pomper, Martin G.
N1 - Publisher Copyright:
© COPYRIGHT 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Radiohalogenated agents are often the first line of pursuit in the development of new radiopharmaceuticals-whether antibodies, peptides, or small molecules-because of their ease of synthesis, lack of substantial steric perturbation of the original affinity agent (in some cases, providing enhanced affinity), and capacity to be transformed into therapeutics (in some cases, with a mere switch of an isotope). They often provide proof of a principle before optimization for pharmacokinetics or generation of radiometallated agents, when the latter are necessary. In particular, 18F has been well integrated into normal clinical work flow in the form of 18F-FDG for oncologic imaging, with reliable daily production and distribution to sites for immediate use, without the need for on-site preparation. Here we discuss radiohalogenated versions of imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA); these were among the first such agents to be synthesized and used clinically. PSMA is highly expressed on prostate cancer epithelial cells and is currently being extensively investigated around the world as a target for imaging and therapy of prostate cancer. Additionally, the presence of PSMA on nonprostate tumor neovasculature has opened the possibility of PSMA-targeted molecules as generalizable cancer imaging and therapy agents. We focus on 18F-labeled agents for PET, as they begin to redefine-along with the corresponding 68Ga-labeled agents discussed elsewhere in this supplement to The Journal of Nuclear Medicine-the management of prostate cancer across a variety of clinical contexts.
AB - Radiohalogenated agents are often the first line of pursuit in the development of new radiopharmaceuticals-whether antibodies, peptides, or small molecules-because of their ease of synthesis, lack of substantial steric perturbation of the original affinity agent (in some cases, providing enhanced affinity), and capacity to be transformed into therapeutics (in some cases, with a mere switch of an isotope). They often provide proof of a principle before optimization for pharmacokinetics or generation of radiometallated agents, when the latter are necessary. In particular, 18F has been well integrated into normal clinical work flow in the form of 18F-FDG for oncologic imaging, with reliable daily production and distribution to sites for immediate use, without the need for on-site preparation. Here we discuss radiohalogenated versions of imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA); these were among the first such agents to be synthesized and used clinically. PSMA is highly expressed on prostate cancer epithelial cells and is currently being extensively investigated around the world as a target for imaging and therapy of prostate cancer. Additionally, the presence of PSMA on nonprostate tumor neovasculature has opened the possibility of PSMA-targeted molecules as generalizable cancer imaging and therapy agents. We focus on 18F-labeled agents for PET, as they begin to redefine-along with the corresponding 68Ga-labeled agents discussed elsewhere in this supplement to The Journal of Nuclear Medicine-the management of prostate cancer across a variety of clinical contexts.
KW - At
KW - Biochemical recurrence
KW - F
KW - PET
KW - Prostate-specific membrane antigen
UR - http://www.scopus.com/inward/record.url?scp=84991409042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991409042&partnerID=8YFLogxK
U2 - 10.2967/jnumed.115.170175
DO - 10.2967/jnumed.115.170175
M3 - Article
C2 - 27694179
AN - SCOPUS:84991409042
SN - 0161-5505
VL - 57
SP - 90S-96S
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
ER -